Bolt Biotherapeutics Inc (BOLT) USD0.00001

Sell:$4.50Buy:$4.65$0.13 (2.77%)

Prices delayed by at least 15 minutes
Sell:$4.50
Buy:$4.65
Change:$0.13 (2.77%)
Deal now
Prices delayed by at least 15 minutes
Sell:$4.50
Buy:$4.65
Change:$0.13 (2.77%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Key people

William P. Quinn
President, Chief Executive Officer, Chief Financial Officer, Director
Grant Yonehiro
Chief Operating Officer
Laura Berner
Independent Director
Jakob Dupont
Independent Director
Kathleen D. Laporte
Independent Director
Brian O'Callaghan
Independent Director
Nicole Onetto
Independent Director
Click to see more

Key facts

  • Shares in issue
    1.92m
  • EPIC
    BOLT
  • ISIN
    US0977022039
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $9.00m
  • Employees
    52
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.